Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen
2001
Targeting Lung Cancer with Antibody-Modified Superantigen
Sample size: 7
publication
Evidence: moderate
Author Information
Author(s): Forsberg G, Ohlsson L, Brodin T, Björk P, Lando P A, Shaw D, Stern P L, Dohlsten M
Primary Institution: Active Biotech Research AB
Hypothesis
Can an antibody-targeted superantigen effectively activate T-cells to destroy non-small-cell lung carcinoma (NSCLC) cells?
Conclusion
The antibody-targeted superantigen 5T4FabV13-SEAD227A shows promising effectiveness in reducing tumor mass in human NSCLC.
Supporting Evidence
- 5T4FabV13-SEAD227A bound the 5T4 antigen with a Kd of 1.2 nM.
- 7 out of 7 NSCLC samples showed tumor reactivity to 5T4FabV13-SEAD227A.
- 5T4FabV13-SEAD227A induced significant T-cell-dependent killing of Calu-1 cells.
Takeaway
Researchers created a special protein that helps the immune system fight lung cancer, and it worked well in tests.
Methodology
The study involved constructing a fusion protein and testing its effectiveness in vitro and in SCID mice.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website